CN116615243A - 使用右美托咪啶盐酸盐治疗躁郁症和精神病 - Google Patents

使用右美托咪啶盐酸盐治疗躁郁症和精神病 Download PDF

Info

Publication number
CN116615243A
CN116615243A CN202180069020.2A CN202180069020A CN116615243A CN 116615243 A CN116615243 A CN 116615243A CN 202180069020 A CN202180069020 A CN 202180069020A CN 116615243 A CN116615243 A CN 116615243A
Authority
CN
China
Prior art keywords
dexmedetomidine
pharmaceutically acceptable
subject
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180069020.2A
Other languages
English (en)
Chinese (zh)
Inventor
F·尤卡
R·里辛格
M·德维沃
F·波斯特马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxcel Therapeutics Inc
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of CN116615243A publication Critical patent/CN116615243A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180069020.2A 2020-10-08 2021-10-08 使用右美托咪啶盐酸盐治疗躁郁症和精神病 Pending CN116615243A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08
PCT/US2021/054171 WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Publications (1)

Publication Number Publication Date
CN116615243A true CN116615243A (zh) 2023-08-18

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180069020.2A Pending CN116615243A (zh) 2020-10-08 2021-10-08 使用右美托咪啶盐酸盐治疗躁郁症和精神病

Country Status (11)

Country Link
US (1) US20240024289A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545372A (cg-RX-API-DMAC7.html)
KR (1) KR20230084186A (cg-RX-API-DMAC7.html)
CN (1) CN116615243A (cg-RX-API-DMAC7.html)
AU (1) AU2021356687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195133A1 (cg-RX-API-DMAC7.html)
IL (1) IL301971A (cg-RX-API-DMAC7.html)
MX (1) MX2023003993A (cg-RX-API-DMAC7.html)
TW (1) TW202228682A (cg-RX-API-DMAC7.html)
WO (1) WO2022076818A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117412747A (zh) * 2021-02-26 2024-01-16 比奥克斯塞尔医疗股份有限公司 用于治疗激越的方法和组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797252A (zh) * 2012-10-15 2015-07-22 奥赖恩公司 减轻噪音厌恶的兽医方法
CN110337290A (zh) * 2016-12-31 2019-10-15 比奥克斯塞尔医疗股份有限公司 舌下右旋美托咪啶用于治疗激越的用途
CN114375191A (zh) * 2019-07-19 2022-04-19 比奥克斯塞尔医疗股份有限公司 非镇静的右美托咪定治疗方案

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797252A (zh) * 2012-10-15 2015-07-22 奥赖恩公司 减轻噪音厌恶的兽医方法
CN110337290A (zh) * 2016-12-31 2019-10-15 比奥克斯塞尔医疗股份有限公司 舌下右旋美托咪啶用于治疗激越的用途
CN114375191A (zh) * 2019-07-19 2022-04-19 比奥克斯塞尔医疗股份有限公司 非镇静的右美托咪定治疗方案

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV: ""Dexmedetomidine in the Treatment of Agitation Associated WithSchizophrenia (SERENITY l)"", pages 22, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04268303> *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117412747A (zh) * 2021-02-26 2024-01-16 比奥克斯塞尔医疗股份有限公司 用于治疗激越的方法和组合物

Also Published As

Publication number Publication date
MX2023003993A (es) 2023-05-24
AU2021356687A1 (en) 2023-06-15
KR20230084186A (ko) 2023-06-12
IL301971A (en) 2023-06-01
TW202228682A (zh) 2022-08-01
US20240024289A1 (en) 2024-01-25
EP4225305A1 (en) 2023-08-16
JP2023545372A (ja) 2023-10-30
EP4225305A4 (en) 2024-10-23
CA3195133A1 (en) 2022-04-14
AU2021356687A9 (en) 2024-10-03
WO2022076818A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
TWI905080B (zh) 含右美托咪啶(dexmedetomidine)之膜調配物及其製造方法
TWI871342B (zh) 非鎮靜之右美托咪啶(dexmedetomidine)治療方案
US20240024289A1 (en) Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
US12138247B2 (en) Non-sedating dexmedetomidine treatment regimens
TW202317101A (zh) 治療抑鬱狀態之方法
HK40078379A (en) Film formulations containing dexmedetomidine and methods of producing them
EP4731214A1 (en) Dexmedetomidine treatment regimens
TW202610650A (zh) 用於增強鎮靜之咪達唑侖及氯胺酮

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230818